TEVA PHARMACEUTICAL INDUSTRIES LTD Quarterly Other Assets, Noncurrent in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of noncurrent assets classified as other.
Summary
Teva Pharmaceutical Industries Ltd quarterly Other Assets, Noncurrent history and growth rate from Q1 2010 to Q3 2024.
  • Teva Pharmaceutical Industries Ltd Other Assets, Noncurrent for the quarter ending September 30, 2024 was $459M, a 3.77% decline year-over-year.
Other Assets, Noncurrent, Quarterly (USD)
Other Assets, Noncurrent, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $459M -$18M -3.77% Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $434M -$9M -2.03% Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $470M +$20M +4.44% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $470M +$29M +6.58% Dec 31, 2023 10-Q 2024-11-06
Q3 2023 $477M +$39M +8.9% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $443M -$11M -2.42% Jun 30, 2023 10-Q 2023-08-02
Q1 2023 $450M -$22M -4.66% Mar 31, 2023 10-Q 2023-05-10
Q4 2022 $441M -$74M -14.4% Dec 31, 2022 10-K 2024-02-12
Q3 2022 $438M -$80M -15.4% Sep 30, 2022 10-Q 2022-11-03
Q2 2022 $454M -$76M -14.3% Jun 30, 2022 10-Q 2022-07-27
Q1 2022 $472M -$52M -9.92% Mar 31, 2022 10-Q 2022-05-03
Q4 2021 $515M -$23M -4.28% Dec 31, 2021 10-K 2023-02-10
Q3 2021 $518M -$304M -37% Sep 30, 2021 10-Q 2021-10-27
Q2 2021 $530M -$30M -5.36% Jun 30, 2021 10-Q 2021-07-28
Q1 2021 $524M -$26M -4.73% Mar 31, 2021 10-Q 2021-04-28
Q4 2020 $538M -$53M -8.97% Dec 31, 2020 10-K 2022-02-09
Q3 2020 $822M +$95M +13.1% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $560M -$161M -22.3% Jun 30, 2020 10-Q 2020-08-05
Q1 2020 $550M -$206M -27.2% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 $591M -$140M -19.2% Dec 31, 2019 10-K 2021-02-10
Q3 2019 $727M +$5M +0.69% Sep 30, 2019 10-Q 2019-11-07
Q2 2019 $721M -$85M -10.5% Jun 30, 2019 10-Q 2019-08-07
Q1 2019 $756M -$76M -9.14% Mar 31, 2019 10-Q 2019-05-02
Q4 2018 $731M -$201M -21.6% Dec 31, 2018 10-K 2020-02-21
Q3 2018 $722M -$327M -31.2% Sep 30, 2018 10-Q 2018-11-01
Q2 2018 $806M -$439M -35.3% Jun 30, 2018 10-Q 2018-08-02
Q1 2018 $832M -$487M -36.9% Mar 31, 2018 10-Q 2018-05-03
Q4 2017 $932M -$303M -24.5% Dec 31, 2017 10-K 2019-02-19
Q3 2017 $1.05B -$1.02B -49.2% Sep 30, 2017 6-K 2017-11-02
Q2 2017 $1.25B -$1.39B -52.8% Jun 30, 2017 6-K 2017-08-03
Q1 2017 $1.32B -$1.34B -50.4% Mar 31, 2017 6-K 2017-05-11
Q4 2016 $1.24B -$1.11B -47.2% Dec 31, 2016 10-K 2018-02-12
Q3 2016 $2.06B -$405M -16.4% Sep 30, 2016 6-K 2016-11-15
Q2 2016 $2.64B -$534M -16.8% Jun 30, 2016 6-K 2016-08-04
Q1 2016 $2.66B +$949M +55.4% Mar 31, 2016 6-K 2016-05-09
Q4 2015 $2.34B +$772M +49.2% Dec 31, 2015 20-F 2017-02-15
Q3 2015 $2.47B +$990M +66.9% Sep 30, 2015 6-K 2015-10-29
Q2 2015 $3.17B +$1.7B +116% Jun 30, 2015 6-K 2015-07-30
Q1 2015 $1.71B +$242M +16.5% Mar 31, 2015 6-K 2015-04-30
Q4 2014 $1.57B -$127M -7.49% Dec 31, 2014 20-F 2016-02-11
Q3 2014 $1.48B -$53M -3.46% Sep 30, 2014 6-K 2014-10-30
Q2 2014 $1.47B +$70M +5% Jun 30, 2014 6-K 2014-07-31
Q1 2014 $1.47B +$85M +6.14% Mar 31, 2014 6-K 2014-05-02
Q4 2013 $1.7B +$358M +26.8% Dec 31, 2013 20-F 2015-02-09
Q3 2013 $1.53B +$1.38B +935% Sep 30, 2013 6-K 2013-10-31
Q2 2013 $1.4B +$1.29B +1149% Jun 30, 2013 6-K 2013-08-01
Q1 2013 $1.39B +$1.22B +750% Mar 31, 2013 6-K 2013-05-02
Q4 2012 $1.34B +$205M +18.1% Dec 31, 2012 20-F 2014-02-10
Q3 2012 $148M +$72M +94.7% Sep 30, 2012 6-K 2012-11-01
Q2 2012 $112M +$24M +27.3% Jun 30, 2012 6-K 2012-08-02
Q1 2012 $163M +$136M +504% Mar 31, 2012 6-K 2012-05-09
Q4 2011 $1.13B +$995M +721% Dec 31, 2011 20-F 2013-02-12
Q3 2011 $76M -$743M -90.7% Sep 30, 2011 6-K 2011-11-02
Q2 2011 $88M -$542M -86% Jun 30, 2011 6-K 2011-07-28
Q1 2011 $27M -$576M -95.5% Mar 31, 2011 6-K 2011-05-11
Q4 2010 $138M Dec 31, 2010 20-F 2012-02-17
Q3 2010 $819M Sep 30, 2010 6-K 2010-11-02
Q2 2010 $630M Jun 30, 2010 6-K 2010-07-27
Q1 2010 $603M Mar 31, 2010 6-K 2010-05-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.